DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

11:35am EDT
Change (% chg)

€1.47 (+2.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for DBV.PA


DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)


Beta: -0.03
Market Cap(Mil.): €1,013.32
Shares Outstanding(Mil.): 19.21
Dividend: --
Yield (%): --


  DBV.PA Industry Sector
P/E (TTM): -- 35.83 39.81
EPS (TTM): -1.49 -- --
ROI: -29.67 17.03 16.23
ROE: -30.82 17.93 17.36
Search Stocks

BRIEF-DBV Technologies announces completion of part A of the miles study about Viaskin Milk

* Announces completion of part A of the miles study evaluating the safety of Viaskin Milk in pediatric cow's milk allergy

30 Jun 2015

REFILE-BRIEF-DBV Technologies SA confirms initiation of Viaskin Peanut global phase III trial

* Confirms planned initiation of Viaskin peanut global phase III clinical trial in children following end-of-phase II meeting with FDA and PIP approval by EMA

23 Jun 2015

BRIEF-Data published on use of DBV Technologies' Viaskin to boost whooping cough immunity

* Key scientific data demonstrating that epicutaneous administration may reactivate protective immunity against pertussis in an experimental model published in Vaccine

10 Jun 2015

BRIEF-DBV Technologies to present new clinical and scientific data

* Presents clinical and scientific data at the EAACI congress

08 Jun 2015

BRIEF-DBV Technologies announces EMA PDCO positive opinion on Viaskin peanut treatment investigation

* Announces EMA paediatric committee (PDCO) positive opinion on the paediatric investigation plan for Viaskin peanut for the treatment of peanut allergic children

04 Jun 2015

BRIEF-DBV Technologies Q1 total income rises to 1.5 mln euros

* Reports for first three months of 2015, total income reached 1,453,706 euros ($1.59 million), up from 1,277,349 euros for same period in 2014

29 Apr 2015

BRIEF-DBV Technologies receives FDA breakthrough therapy designation for Viaskin peanut

* Receives FDA breakthrough therapy designation for Viaskin peanut for the treatment of peanut allergy in children

09 Apr 2015

BRIEF-DBV Technologies FY net loss widens to 24.0 million euros

* Reports FY net loss of 24.0 million euros ($26.22 million) versus loss of 19.3 million year ago

25 Mar 2015

BRIEF-DBV Technologies FY revenue rises to 4.8 mln euros

* FY 2014 revenue 4.8 million euros ($5.4 million) versus 3.82 million euros last year Source text for Eikon: Further company coverage: ($1 = 0.8863 euros) (Gdynia Newsroom)

29 Jan 2015

BRIEF-DBV Technologies announces publication on Epicutaneous Immunotherapy

* Announces publication demonstrating early treatment with Epicutaneous Immunotherapy (EPIT) using Viaskin may induce protection from sensitization to other allergens

12 Jan 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks